Search research articles
Contact Us
Filters
Showing results (91-100 of 102) with videos related to
Page
of 11
Sort By:
Trials
|
October 10, 2025
Core outcome domain sets for clinical trials in epidermolysis bullosa - a COSEB protocol to achieve consensus on "what" to measure
Eva W H Korte, Peter C van den Akker, Dimitra Kiritsi, et al.
Journal of the American Academy of Dermatology
|
February 8, 2018
Diacerein orphan drug development for epidermolysis bullosa simplex: A phase 2/3 randomized, placebo-controlled, double-blind clinical trial
Verena Wally, Alain Hovnanian, Juliette Ly, et al.
The Journal of Dermatology
|
January 24, 2025
Repurposing diacerein for the treatment of chronic wounds in recessive-dystrophic epidermolysis bullosa patients by modulating matrix metalloproteinase-9 expression
Sonja Dorfer, Michael Ablinger, Monika Wimmer, et al.
Scientific Reports
|
July 9, 2020
A novel humanized mouse model to study the function of human cutaneous memory T cells in vivo in human skin
Maria M Klicznik, Ariane Benedetti, Laura M Gail, et al.
Journal of Drugs in Dermatology : JDD
|
June 5, 2023
Diacerein 1% Ointment for the Treatment of Epidermolysis Bullosa Simplex: A Randomized, Controlled Trial
Joyce Teng, Amy S. Paller, Anna L. Bruckner, et al.
Science Advances
|
June 24, 2026
Harnessing skin-resident γδ T cells for immunotherapy in cutaneous squamous cell carcinoma
Giorgia Nasi, Leonie C Schöftner, Lara Ronacher, et al.
Orphanet Journal of Rare Diseases
|
November 9, 2021
Impact of low-dose calcipotriol ointment on wound healing, pruritus and pain in patients with dystrophic epidermolysis bullosa: A randomized, double-blind, placebo-controlled trial
Christina Guttmann-Gruber, Josefina Piñón Hofbauer, Birgit Tockner, et al.
The British Journal of Dermatology
|
June 12, 2024
Towards a roadmap for COSEB: the next steps in harmonization of outcomes for epidermolysis bullosa
Eva W H Korte, Anna M G Pasmooij, Maria C Bolling, et al.
The British Journal of Dermatology
|
September 8, 2023
MicroRNA-200b-mediated reversion of a spectrum of epithelial-to-mesenchymal transition states in recessive dystrophic epidermolysis bullosa squamous cell carcinomas
Julia Illmer, Roland Zauner, Josefina Piñón Hofbauer, et al.
Scientific Reports
|
September 9, 2018
Low-dose calcipotriol can elicit wound closure, anti-microbial, and anti-neoplastic effects in epidermolysis bullosa keratinocytes
Christina Guttmann-Gruber, Birgit Tockner, Cornelia Scharler, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 102) with videos related to
Sort By:
Page
of 11
Trials
|
October 10, 2025
Core outcome domain sets for clinical trials in epidermolysis bullosa - a COSEB protocol to achieve consensus on "what" to measure
Eva W H Korte, Peter C van den Akker, Dimitra Kiritsi, et al.
Journal of the American Academy of Dermatology
|
February 8, 2018
Diacerein orphan drug development for epidermolysis bullosa simplex: A phase 2/3 randomized, placebo-controlled, double-blind clinical trial
Verena Wally, Alain Hovnanian, Juliette Ly, et al.
The Journal of Dermatology
|
January 24, 2025
Repurposing diacerein for the treatment of chronic wounds in recessive-dystrophic epidermolysis bullosa patients by modulating matrix metalloproteinase-9 expression
Sonja Dorfer, Michael Ablinger, Monika Wimmer, et al.
Scientific Reports
|
July 9, 2020
A novel humanized mouse model to study the function of human cutaneous memory T cells in vivo in human skin
Maria M Klicznik, Ariane Benedetti, Laura M Gail, et al.
Journal of Drugs in Dermatology : JDD
|
June 5, 2023
Diacerein 1% Ointment for the Treatment of Epidermolysis Bullosa Simplex: A Randomized, Controlled Trial
Joyce Teng, Amy S. Paller, Anna L. Bruckner, et al.
Science Advances
|
June 24, 2026
Harnessing skin-resident γδ T cells for immunotherapy in cutaneous squamous cell carcinoma
Giorgia Nasi, Leonie C Schöftner, Lara Ronacher, et al.
Orphanet Journal of Rare Diseases
|
November 9, 2021
Impact of low-dose calcipotriol ointment on wound healing, pruritus and pain in patients with dystrophic epidermolysis bullosa: A randomized, double-blind, placebo-controlled trial
Christina Guttmann-Gruber, Josefina Piñón Hofbauer, Birgit Tockner, et al.
The British Journal of Dermatology
|
June 12, 2024
Towards a roadmap for COSEB: the next steps in harmonization of outcomes for epidermolysis bullosa
Eva W H Korte, Anna M G Pasmooij, Maria C Bolling, et al.
The British Journal of Dermatology
|
September 8, 2023
MicroRNA-200b-mediated reversion of a spectrum of epithelial-to-mesenchymal transition states in recessive dystrophic epidermolysis bullosa squamous cell carcinomas
Julia Illmer, Roland Zauner, Josefina Piñón Hofbauer, et al.
Scientific Reports
|
September 9, 2018
Low-dose calcipotriol can elicit wound closure, anti-microbial, and anti-neoplastic effects in epidermolysis bullosa keratinocytes
Christina Guttmann-Gruber, Birgit Tockner, Cornelia Scharler, et al.
Page
of 11